Salt Selection in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Salt Selection in Drug Development
The selection of an appropriate salt form for a potential drug candidate is an opportunity to modulate its characteristics to improve bioavailability, stability, manufacturability, and patient compliance.


Pharmaceutical Technology
Volume 3, Issue 32

38. USP, USP 29–NF 24 (US Pharmacopeial Convention, Rockville, MD, 2006).

39. K.R. Morris et al., "An Integrated Approach to the Selection of Optimal Salt Form for a New Drug Candidate," Int. J. Pharm. 105 (3), 209–217 (1994).

40. R. Teraoka, M. Otsuka, and Y. Matsuda, "Effects of Temperature and Relative Humidity on the Solid-State Chemical Stability of Ranitidine Hydrochloride," J. Pharm. Sci. 82 (6), 601–604 (1993).

41. H.Y. Ando and G.W. Radebaugh, "Preformulation," in Remington: The Science and Practice of Pharmacy, II, A.R. Gennaro, Ed. (Lippincott Williams and Wilkins, Baltimore, MD, 20th ed., 2002), pp. 700–720.

42. J.F. Remenar et al., "Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization: The Case of Sertraline," Org. Proc. Res. Dev. 7 (6), 990–996 (2003).

43. C.R. Gardner, C.T. Walsh, and . Almarsson, "Drugs as Materials: Valuing Physical Form in Drug Discovery," Nat. Rev. Drug. Discov. 3 (11), 926–934 (2004).

44. "Ophthalmic/Otic Dosage Forms," http://www.cop.ufl.edu/safezone/prokai/pha5100/eye.htm, accessed Dec. 20, 2006.

45. Solvias, "Introduction: Solid-State Development," http://www.solvias.com/documents/Dokumente/Downloads_news/Solvias_Salt_and_Polymorphism_Programs.pdf, accessed Dec. 30, 2006.

46. European Agency for the Evaluation of Medicinal Products, "Note for Guidance on the Investigation of Bioavailability and Bioequivalence" (EMEA, London, UK, 2001).

47. FDA, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (FDA, Rockville, MD, 2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here